Nkarta, Inc. Common Stock
$2.87
-$0.01 (-0.35%)
$2.83Day Range$3.06
Key Statistics
Market Cap
$206.28M
Shares Outstanding
71.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 10, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$2.93
Day High
$3.06
Day Low
$2.83
Volume
642.2K
VWAP
$2.91
Prev Close
$2.88
Transactions
--
Acc. Volume
--
About Nkarta, Inc. Common Stock
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
PHARMACEUTICAL PREPARATIONSSIC 2834106 employees1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080(925) 407-1049IPO Jul 10, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001787400
- Composite FIGI
- BBG00JXHS9G7
- Share Class FIGI
- BBG00JXHS9H6
- Ticker Root
- NKTX
- SIC Code
- 2834
About Nkarta, Inc. Common Stock (NKTX) Stock
Nkarta, Inc. Common Stock (NKTX) closed the 2026-09-16 session at $2.87, down 0.35% versus the previous close (-0.01). The stock opened at $2.93 and traded between $2.83 and $3.06 during that session. Session trading volume was 642K shares. The volume-weighted average price (VWAP) is $2.91.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Nkarta, Inc. Common Stock has a market capitalization of $206.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NKTX is listed on the XNAS exchange. The company employs approximately 106 people. Nkarta, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2020-07-10.
On this page you can find market NKTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.